Literature DB >> 11564411

Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus.

N Hájos1, C Ledent, T F Freund.   

Abstract

Psychoactive effects of cannabinoids are thought to be mediated, at least in part, by suppression of both glutamate and GABA release via CB1 cannabinoid receptor. Two types of cannabinoid receptor (CB1 and CB2) have been cloned so far. The CB1 receptors are abundantly expressed in the nervous system, whereas CB2 receptors are limited to lymphoid organs (Matsuda et al., 1990; Munro et al., 1993). Immunocytochemical and electrophysiological studies revealed that in the hippocampus CB1 receptors are expressed on axon terminals of GABAergic inhibitory interneurons (Tsou et al., 1999; Katona et al., 1999) and activation of these receptors decreases GABA release (Hájos et al., 2000). Other physiological studies pointed out the involvement of CB1 receptors in the modulation of hippocampal glutamatergic synaptic transmission and long-term potentiation (Stella et al., 1997; Misner and Sullivan, 1999), but anatomical studies could not confirm the existence of CB1 receptors on glutamatergic terminals. Here we examined cannabinoid actions on both glutamatergic and GABAergic synaptic transmission in the hippocampus of wild type (CB1+/+) and CB1 receptor knockout mice (CB1-/-). The synthetic cannabinoid agonist WIN55,212-2 reduced the amplitudes of excitatory postsynaptic currents in both wild type and CB1-/- mice, while inhibitory postsynaptic currents were decreased only in wild type mice, but not in CB1-/- animals. Our findings are consistent with a CB1 cannabinoid receptor-dependent modulation of GABAergic postsynaptic currents, but a novel cannabinoid-sensitive receptor must be responsible for the inhibition of glutamatergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564411     DOI: 10.1016/s0306-4522(01)00287-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  109 in total

1.  Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.

Authors:  P T Nguyen; D E Selley; L J Sim-Selley
Journal:  Neuroimage       Date:  2010-05-06       Impact factor: 6.556

2.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists.

Authors:  Elena Cichero; Sara Cesarini; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2010-02-20       Impact factor: 1.810

5.  Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus.

Authors:  Alexander F Hoffman; Alice M Macgill; Dennison Smith; Murat Oz; Carl R Lupica
Journal:  Eur J Neurosci       Date:  2005-11       Impact factor: 3.386

Review 6.  Cannabinoid receptors and endocannabinoids: evidence for new players.

Authors:  Ken Mackie; Nephi Stella
Journal:  AAPS J       Date:  2006-04-28       Impact factor: 4.009

7.  [Endogenous cannabinoid system. Effect on neuronal plasticity and pain memory].

Authors:  S C Azad; V Huge; P Schöps; C Hilf; A Beyer; H-U Dodt; G Rammes; W Zieglgänsberger
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

8.  Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.

Authors:  Eberhard Schlicker; Agnes Redmer; Andre Werner; Markus Kathmann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 9.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.

Authors:  T J Price; G Helesic; D Parghi; K M Hargreaves; C M Flores
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.